Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

The relationship between central (cerebrospinal fluid [CSF]) and peripheral (plasma) monoaminergic metabolites and psychotic symptoms was examined in 22 drug-free schizophrenic inpatients. The CSF homovanillic acid levels did not differ significantly between patients and normal controls (n = 33). The CSF homovanillic acid levels, however, were negatively correlated with ratings of psychosis and positive symptoms, and the CSF homovanillic acid and 5-hydroxyindoleacetic acid levels correlated negatively with individual deficit symptoms. Stepwise and hierarchical multiple-regression analysis revealed that among monoaminergic measures, only the CSF and plasma homovanillic acid levels contributed significantly to the total Brief Psychiatric Rating Scale and positive symptom variance with negative and positive partial correlations, respectively. Levels of CSF 3-methoxy-4-hydroxyphenylglycol, but not of CSF norepinephrine, were significantly elevated in the schizophrenic patients compared with controls, and plasma 3-methoxy-4-hydroxyphenylglycol levels were positively correlated with negative symptoms. We discuss the potential implications of these findings for a model of dopaminergic dysfunction in schizophrenia involving distinct cortical and subcortical contributions.

[1]  O. Wolkowitz,et al.  Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia. , 1990, Modern problems of pharmacopsychiatry.

[2]  J. Hsiao,et al.  Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions. , 1989, Archives of general psychiatry.

[3]  Jeffrey K. Yao,et al.  CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal , 1989, Biological Psychiatry.

[4]  John M. Davis,et al.  Plasma and CSF HVA before and after pharmacological treatment , 1989, Psychiatry Research.

[5]  E. Widerlöv A Critical Appraisal of CSF Monoamine Metabolite Studies in Schizophrenia , 1988, Annals of the New York Academy of Sciences.

[6]  D. Weinberger,et al.  Mesocortical Dopaminergic Function and Human Cognition , 1988, Annals of the New York Academy of Sciences.

[7]  J. Kelsoe,et al.  Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients , 1988, Annals of the New York Academy of Sciences.

[8]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[9]  R. Wyatt,et al.  Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. , 1988, Archives of general psychiatry.

[10]  O. Wolkowitz,et al.  Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers , 1988, Psychiatry Research.

[11]  J. Kelsoe,et al.  Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. , 1988, Archives of general psychiatry.

[12]  D. Weinberger,et al.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. , 1988, Archives of general psychiatry.

[13]  C. Bowden,et al.  Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin. , 1988, Archives of general psychiatry.

[14]  K. Davis,et al.  A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. , 1988, Archives of general psychiatry.

[15]  A. Friedhoff,et al.  Plasma homovanillic acid as a predictor of response to neuroleptics. , 1988, Archives of general psychiatry.

[16]  M. Koulu,et al.  A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid , 1988, Brain Research Bulletin.

[17]  I. Kopin,et al.  Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[18]  E. Yeh,et al.  Plasma homovanillic acid levels and subtyping of schizophrenia , 1988, Psychiatry Research.

[19]  W. Potter,et al.  Bupropion in depression. I. Biochemical effects and clinical response. , 1988, Archives of general psychiatry.

[20]  D. Pickar,et al.  Perspectives on a time-dependent model of neuroleptic action. , 1988, Schizophrenia bulletin.

[21]  T. Goldberg,et al.  Probing prefrontal function in schizophrenia with neuropsychological paradigms. , 1988, Schizophrenia bulletin.

[22]  D. Weinberger,et al.  Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. , 1988, Schizophrenia bulletin.

[23]  O. Wolkowitz,et al.  Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[24]  J. Hsiao,et al.  Monoamine neurotransmitter interactions and the prediction of antidepressant response. , 1987, Archives of general psychiatry.

[25]  K. Davis,et al.  Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[26]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[27]  L. DeLisi,et al.  Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. , 1987, Life sciences.

[28]  O. Wolkowitz,et al.  Clinical and biochemical effects of verapamil administration to schizophrenic patients. , 1987, Archives of general psychiatry.

[29]  C. Bowden,et al.  Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia , 1986, Psychiatry Research.

[30]  M. Linnoila,et al.  Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. , 1986, Archives of general psychiatry.

[31]  H. Scheinin Enhanced Noradrenergic Neuronal Activity Increases Homovanillic Acid Levels in Cerebrospinal Fluid , 1986, Journal of neurochemistry.

[32]  M Linnoila,et al.  Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. , 1986, Archives of general psychiatry.

[33]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. , 1986, Archives of general psychiatry.

[34]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.

[35]  M Linnoila,et al.  Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. , 1986, Journal of psychiatric research.

[36]  I. Kopin,et al.  Catecholamine metabolism: basic aspects and clinical significance. , 1985, Pharmacological reviews.

[37]  M. Stanley,et al.  Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. , 1985, Life sciences.

[38]  R. Hamer,et al.  Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population , 1985, Psychiatry Research.

[39]  L. Lindström Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: Correlations to symptomatology and family history , 1985, Psychiatry Research.

[40]  K. Davis,et al.  Plasma homovanillic acid concentration and the severity of schizophrenic illness. , 1985, Science.

[41]  S. Galderisi,et al.  Relationship between CSF noradrenaline levels, C‐EEG indicators of activation and psychosis ratings in drug‐free schizophrenic patients , 1985, Acta psychiatrica Scandinavica.

[42]  B. Shaywitz,et al.  CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. , 1984, The American journal of psychiatry.

[43]  K. Davis,et al.  Acute and chronic effects of neuroleptic drugs on plasma and brain homovanilic acid in the rat , 1984, Psychiatry Research.

[44]  D. Hommer,et al.  Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. , 1984, Science.

[45]  J. Sowers,et al.  Circadian variation in plasma dopamine levels in man , 1984, Journal of endocrinological investigation.

[46]  P. Jatlow,et al.  Plasma catecholamine metabolites and early response to haloperidol. , 1984, The Journal of clinical psychiatry.

[47]  O. Smith,et al.  Central neural integration for the control of autonomic responses associated with emotion. , 1984, Annual review of neuroscience.

[48]  M. Scheinin,et al.  Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. , 2009, Acta pharmacologica et toxicologica.

[49]  B. Berggren,et al.  Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers , 1983, Psychiatry Research.

[50]  M. Scheinin,et al.  Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-performance liquid chromatography using electrochemical detection. , 1983, Analytical biochemistry.

[51]  L. Sternberg,et al.  Isotopic Composition of Cellulose from C3, C4, and CAM Plants Growing Near One Another , 1983, Science.

[52]  S. Marder,et al.  Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. , 1983, Science.

[53]  R. Roth,et al.  Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. , 1983, Life sciences.

[54]  M. Scheinin,et al.  Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. , 1983, Analytical biochemistry.

[55]  G. Reynolds,et al.  Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients , 1983, Psychiatry Research.

[56]  R. Roth,et al.  Pharmacology of mesocortical dopamine neurons. , 1983, Pharmacological reviews.

[57]  P. Woolf,et al.  Evaluation of the dopamine response to stress in man. , 1983, The Journal of clinical endocrinology and metabolism.

[58]  I. Kopin,et al.  Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. , 1983, Science.

[59]  W. Gattaz,et al.  CSF monoamine metabolites in schizophrenic patients , 1982, Acta psychiatrica Scandinavica.

[60]  B. Berggren,et al.  Computed tomography of the brain in patients with acute psychosis and in healthy volunteers , 1982, Acta psychiatrica Scandinavica.

[61]  W. Bunney,et al.  The effect of pimozide on CSF norepinephrine in schizophrenia. , 1981, The American journal of psychiatry.

[62]  H. Landis,et al.  Catecholamine metabolites in human plasma as indices of brain function: effects of debrisoquin. , 1980, Life sciences.

[63]  B. Shanley,et al.  Noradrenergic Overactivity in Chronic Schizophrenia: Evidence Based on Cerebrospinal Fluid Noradrenaline and Cyclic Nucleotide Concentrations , 1980, British Journal of Psychiatry.

[64]  C. Carter,et al.  Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.

[65]  H. Kraemer,et al.  CSF monoamine metabolites in depression and schizophrenia. , 1980, The American journal of psychiatry.

[66]  R. Post,et al.  Schizophrenia: elevated cerebrospinal fluid norepinephrine. , 1980, Science.

[67]  T. Chase Neurochemical Alterations in Parkinson's Disease , 1980 .

[68]  J. Wood Sites of Origin and Cerebrospinal Fluid Concentration Gradients , 1980 .

[69]  H. Meltzer,et al.  Clinical processes and central dopaminergic activity in psychotic disorders. , 1980, Communications in psychopharmacology.

[70]  H. E. Rosvold,et al.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.

[71]  R. Roth,et al.  3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. , 1979, European journal of pharmacology.

[72]  J. Glowinski,et al.  Selective activation of the mesocortical DA system by stress , 1976, Nature.

[73]  Jacob Cohen,et al.  Applied multiple regression/correlation analysis for the behavioral sciences , 1979 .

[74]  F. Goodwin,et al.  Cerebrospinal fluid amine metabolites in acute schizophrenia. , 1975, Archives of general psychiatry.

[75]  J. Korf,et al.  Neuroleptics, catecholamines, and psychoses: a study of their interrelations. , 1975, The American journal of psychiatry.

[76]  M. Bowers Central dopamine turnover in schizophrenic syndromes. , 1974, Archives of general psychiatry.

[77]  R. Rimón,et al.  The content of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. , 1971, Journal of psychosomatic research.

[78]  B. Roos,et al.  Acid Metabolites from Monoamines in Cerebrospinal Fluid of Chronic Schizophrenics , 1969, British Journal of Psychiatry.

[79]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .